F-1/A: Mainz Biomed N.V. Announces Proposed Offering of Ordinary and Pre-Funded Units

Mainz Biomed N.V. is planning a best-efforts offering of ordinary units and pre-funded units to raise capital for its eAArly Detect 2 study, product development, commercial expansion, and debt repayment.

Summary

• Mainz Biomed N.V. is offering up to 2,448,980 ordinary units, each consisting of one ordinary share, one Class A warrant, and one Class B warrant.
• The company is also offering up to 2,448,980 pre-funded units, each consisting of one pre-funded warrant, one Class A warrant, and one Class B warrant.
• The assumed offering price is $2.45 per ordinary unit, based on the closing price of Mainz Biomed's ordinary shares on May 9, 2025.
• The price for each pre-funded unit will be $0.0001 less than the price per ordinary unit.
• The company intends to use the net proceeds from this offering for the eAArly Detect 2 study, the development of its next generation screening product, the commercial expansion of its ColoAlert product, repayment of debt and for general corporate purposes.
• The offering is on a best-efforts basis, and there is no minimum offering amount required.
• The offering will terminate on May 31, 2025, unless the company decides to terminate it earlier.
• Maxim Group LLC is acting as the exclusive placement agent for the offering.
• The company estimates net proceeds of approximately $5,330,000 from this offering, after deducting placement agent fees and estimated offering expenses of approximately $670,000.

Sentiment

Score: 5

Explanation: The document is neutral. It describes a proposed offering, outlining both the potential benefits and risks associated with investing in the company. The financial data presented shows both positive and negative aspects of the company's performance.

Positives

• The offering aims to fund the eAArly Detect 2 study, which is crucial for validating the next-generation mRNA-based CRC screening test.
• Capital raised will support the development of the next-generation screening product, potentially enhancing its market competitiveness.
• Proceeds will be used to expand the commercial reach of the ColoAlert product, increasing revenue opportunities.
• Repayment of debt will improve the company's financial stability.
• The company has broad discretion in the use of the net proceeds from this offering and may use them effectively.

Negatives

• The offering is on a best-efforts basis, meaning there's no guarantee the company will raise the desired amount.
• Investors will experience immediate and substantial dilution as a result of this offering.
• There is no public market for the pre-funded warrants, Class A Warrants or Class B Warrants being offered in this offering.
• The market price of the company's ordinary shares may be volatile and may fluctuate in a way that is disproportionate to its operating performance.
• The company has broad discretion in the use of the net proceeds from this offering and may not use them effectively.

Risks

• The company may not raise the amount of capital it believes is required for its business plans.
• The market price of the company's ordinary shares may be volatile.
• Investors will experience immediate and substantial dilution as a result of this offering.
• The company may issue additional ordinary shares or preferred shares, diluting ownership interests.
• The company does not intend to pay dividends, limiting potential gains on investment.
• FINRA sales practice requirements may limit investors' ability to buy and sell ordinary shares.
• Volatility in the company's ordinary shares price may subject it to securities litigation.
• Nasdaq may delist the company's ordinary shares if it fails to meet continued listing requirements.
• The company has broad discretion in the use of the net proceeds from this offering and may not use them effectively.
• There is no public market for the pre-funded warrants, the Class A Warrants or the Class B Warrants being offered in this offering.
• Holders of the pre-funded warrants, the Class A Warrants or the Class B Warrants purchased in this offering will have no rights as ordinary shareholders until such holders exercise such respective warrants and acquire the company's ordinary shares, except as otherwise provided in the respective warrants.
• If the company enters into privately negotiated warrant inducements with the Prior Warrants, its stock price may be affected and investors may experience substantial dilution.

Future Outlook

The company intends to use the net proceeds from this offering for the eAArly Detect 2 study, the development of its next generation screening product, the commercial expansion of its ColoAlert product, repayment of debt and for general corporate purposes.

Industry Context

The document mentions that Global Market Insights anticipates that the annual market for CRC diagnostics will surpass $30 billion by 2032, highlighting the significant opportunity in the molecular diagnostics market.

Comparison to Industry Standards

• The document compares the CRC and AA sensitivity and specificity results of Mainz Biomed's next-generation mRNA CRC screening test to some competing products.
• The document mentions Quest Diagnostics as a provider of clinical trial laboratory services for the ReconAAsense study, indicating a partnership with a major player in the diagnostics industry.
• The document mentions Thermo Fisher Scientific Inc. as a world leader in serving science, with annual revenue over $40 billion in its latest fiscal year, indicating a collaboration with a major player in the diagnostics industry.

Legal Proceedings

• Mainz filed a lawsuit against an investment bank in 2024 regarding a right of first refusal granted in connection with its initial public offering in 2021.
• The investment bank initiated arbitration proceedings against Mainz with the Financial Industry Regulatory Authority (FINRA).
• The arbitration panel agreed to stay its proceeding in light of the existing lawsuit.
• The company intends to vigorously defend against all claims.

Stakeholder Impact

• Shareholders may experience dilution as a result of the offering.
• The offering aims to fund the eAArly Detect 2 study, which is crucial for validating the next-generation mRNA-based CRC screening test, which could benefit patients.
• The company intends to use the net proceeds from this offering for the eAArly Detect 2 study, the development of its next generation screening product, the commercial expansion of its ColoAlert product, repayment of debt and for general corporate purposes.

Next Steps

• The company will proceed with the best-efforts offering, attempting to sell the ordinary and pre-funded units.
• The company will use the net proceeds from this offering for the eAArly Detect 2 study, the development of its next generation screening product, the commercial expansion of its ColoAlert product, repayment of debt and for general corporate purposes.
• The company will deliver the securities being issued to the investors upon receipt of investor funds for the purchase of the securities offered pursuant to this prospectus on or about , 2025.

Key Dates

Keywords

offering, ordinary units, pre-funded units, warrants, Mainz Biomed, capital raise, ColoAlert, eAArly Detect 2, screening test, diagnostics